Login/Register 
Loading...
United States 
-
United States ($) USD
-
Austria (€) EUR
-
Belgium (€) EUR
-
Denmark (DKK) DKK
-
Finland (€) EUR
-
France (€) EUR
-
Germany (€) EUR
-
Ireland (€) EUR
-
Japan (¥) JPY
-
Luxembourg (€) EUR
-
Netherlands (€) EUR
-
Norway (NOK) NOK
-
Sweden (SEK) SEK
-
Switzerland (CHF) CHF
-
United Kingdom (£) GBP
- If your country is not listed,
click here for Worldwide Ordering
About the webinar
End-to-end contract development and manufacturing services for tailor-made GMP ancillary material for cell therapy manufacturing.
High-quality ancillary materials for bioprocessing—meeting both functional and safety standards—are essential for the consistent and successful manufacturing of cell therapies destined for clinical use.
Building on decades of experience in biologics manufacturing for research applications, BioLegend has expanded our GMP capabilities to support the production of biological materials intended for use as ancillary and raw materials in cell therapy manufacturing.
In this session, Kenta Yamamoto presents an overview of our comprehensive contract development and manufacturing services, highlights our GMP bioprocessing capabilities in alignment with relevant regulatory guidelines (e.g., USP <1043>), and shares project examples demonstrating how our ancillary material solutions can help advance your novel cell therapy to the clinic.
What will you learn?
- Overview of BioLegend’s end-to-end contract development and manufacturing services for producing ancillary materials used in downstream cell therapy manufacturing
- Introduction to key regulatory guidelines for ancillary and raw materials in cell therapy manufacturing (e.g., USP <1043>, EP 5.2.12)
- Case studies showcasing prior projects to illustrate how our services can support the advancement of novel cell therapies toward regulatory approval and clinical application
ProductsHere
Follow Us